For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
SWOG S1806
Trial Overview
Official Title
Testing Combined Chemotherapy and Radiation Therapy With and Without the Use of Atezolizumab Immunotherapy in Muscle Invasive Bladder Cancer
Study Purpose
To compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of the immunotherapy drug atezolizumab, used to treat bladder cancer.
Diagnosis
Patient has bladder cancer that has not spread beyond the bladder.Eligibility
Confirmed Bladder Cancer T2-T4aN0M0
No Prior Chemotherapy for Bladder Cancer
No Prior Radiation
Patients must Sign Approved Informed Consent and Authorization Permitting Release of Personal Health Information
Intervention
- Group 1: Radiation Therapy, One of the Usual Chemotherapy Regimens
- Group 2: Radiation Therapy, One of the Usual Chemotherapy Regimens and the Study Drug, Atezolizumab
- Quality of Life Questionnaires
For more information, visit ClinicalTrials.gov
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
S1806